More recently, androgen receptor pathway inhibitors (ARpI), including androgen receptors targeted agents (ARTA) such as Enzalutamide, Apalutamide, and Darolutamide, and steroidogenesis inhibitors such as Abiraterone, have profoundly impacted the management of advanced prostate cancer. This evidence concerns the gene AR and prostate carcinoma.